Suchergebnisse - "Progression-Free Survival [MeSH]"
-
1
Autoren: et al.
Quelle: British Journal of Cancer. 129(2)
Schlagwörter: 32 Biomedical and Clinical Sciences (for-2020), 3202 Clinical Sciences (for-2020), 3211 Oncology and Carcinogenesis (for-2020), 3204 Immunology (for-2020), Clinical Research (rcdc), Health Disparities (rcdc), Clinical Trials and Supportive Activities (rcdc), 6.1 Pharmaceuticals (hrcs-rac), Cancer (hrcs-hc), Humans (mesh), Antibodies, Monoclonal, Humanized (mesh), Antineoplastic Combined Chemotherapy Protocols (mesh), Carcinoma, Neuroendocrine (mesh), Neuroendocrine Tumors (mesh), Progression-Free Survival (mesh), Humans (mesh), Neuroendocrine Tumors (mesh), Carcinoma, Neuroendocrine (mesh), Antineoplastic Combined Chemotherapy Protocols (mesh), Antibodies, Monoclonal, Humanized (mesh), Progression-Free Survival (mesh), Humans (mesh), Antibodies, Monoclonal, Humanized (mesh), Antineoplastic Combined Chemotherapy Protocols (mesh), Carcinoma, Neuroendocrine (mesh), Neuroendocrine Tumors (mesh), Progression-Free Survival (mesh), 1112 Oncology and Carcinogenesis (for), 1117 Public Health and Health Services (for), Oncology & Carcinogenesis (science-metrix), 3211 Oncology and carcinogenesis (for-2020)
Dateibeschreibung: application/pdf
-
2
Autoren: et al.
Quelle: Cancer Epidemiology Biomarkers & Prevention. 32(8)
Schlagwörter: 32 Biomedical and Clinical Sciences (for-2020), 42 Health Sciences (for-2020), 3211 Oncology and Carcinogenesis (for-2020), Women's Health (rcdc), Breast Cancer (rcdc), Health Disparities (rcdc), Cancer (rcdc), Behavioral and Social Science (rcdc), Cancer (hrcs-hc), Female (mesh), Humans (mesh), Breast Neoplasms (mesh), Carcinoma, Ductal, Breast (mesh), Carcinoma, Lobular (mesh), Progression-Free Survival (mesh), Retrospective Studies (mesh), Residence Characteristics (mesh), Socioeconomic Factors (mesh), Social Deprivation (mesh), Healthcare Disparities (mesh), Middle Aged (mesh), Humans (mesh), Carcinoma, Ductal, Breast (mesh), Carcinoma, Lobular (mesh), Breast Neoplasms (mesh), Retrospective Studies (mesh), Residence Characteristics (mesh), Socioeconomic Factors (mesh), Middle Aged (mesh), Female (mesh), Healthcare Disparities (mesh), Progression-Free Survival (mesh), Social Deprivation (mesh), Female (mesh), Humans (mesh), Breast Neoplasms (mesh), Carcinoma, Ductal, Breast (mesh), Carcinoma, Lobular (mesh), Progression-Free Survival (mesh), Retrospective Studies (mesh), Residence Characteristics (mesh), Socioeconomic Factors (mesh), Social Deprivation (mesh), Healthcare Disparities (mesh), Middle Aged (mesh), 11 Medical and Health Sciences (for), Epidemiology (science-metrix), 32 Biomedical and clinical sciences (for-2020), 42 Health sciences (for-2020)
Dateibeschreibung: application/pdf
-
3
Autoren: et al.
Quelle: Breast Cancer
Schlagwörter: Clinical Trials as Topic, United States Food and Drug Administration, Breast Neoplasms, Antineoplastic Agents, United States, Progression-Free Survival, ddc, Original Article, Breast cancer, Early breast cancer, Cancer drugs, Clinical trials, Antibody-drug conjugates, FDA approval, Value-based pricing, Innovation, Biomarker, Antibody, HER2, Hormone receptor, BRCA, Quality of life, Overall survival, Progression-free survival, Tumor response, Objective response rate, ESMO-MCBS, Metastatic breast cancer, Quality of Life, Humans, United States [MeSH], Progression-Free Survival [MeSH], Antineoplastic Agents/economics [MeSH], United States Food and Drug Administration [MeSH], Quality of Life [MeSH], Breast Neoplasms/mortality [MeSH], Breast Neoplasms/pathology [MeSH], Female [MeSH], Humans [MeSH], Breast Neoplasms/drug therapy [MeSH], Drug Approval [MeSH], Clinical Trials as Topic [MeSH], Antineoplastic Agents/therapeutic use [MeSH], Female, Drug Approval
Dateibeschreibung: application/pdf
-
4
Autoren: et al.
Quelle: Int J Cardiovasc Imaging
The International Journal of Cardiovascular Imaging, 40 (10)Schlagwörter: Male, Adult, Time Factors, Surgical ventricular repair, Ventricular Function, Left, 03 medical and health sciences, 0302 clinical medicine, Predictive Value of Tests, Diastole, Risk Factors, Surgical ventricular restoration, Humans, Heart Aneurysm, Cardiac Surgical Procedures, Retrospective Studies, Aged, Outcome study, Original Paper, Speckle-tracking echocardiography, Reproducibility of Results, Strain rate, Middle Aged, Progression-Free Survival, Echocardiography, Doppler, Left ventricular aneurysm, 3. Good health, Treatment Outcome, Cardiac Surgical Procedures/adverse effects [MeSH], Ventricular Function, Left [MeSH], Aged [MeSH], Heart Aneurysm/mortality [MeSH], Progression-Free Survival [MeSH], Risk Factors [MeSH], Heart Aneurysm/surgery [MeSH], Echocardiography, Doppler [MeSH], Male [MeSH], Female [MeSH], Adult [MeSH], Humans [MeSH], Treatment Outcome [MeSH], Predictive Value of Tests [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Heart Aneurysm/physiopathology [MeSH], Time Factors [MeSH], Reproducibility of Results [MeSH], Diastole [MeSH], Heart Aneurysm/diagnostic imaging [MeSH], Female
Dateibeschreibung: application/application/pdf
-
5
Autoren: et al.
Quelle: Biomarkers. 28(3)
Schlagwörter: 32 Biomedical and Clinical Sciences (for-2020), 3211 Oncology and Carcinogenesis (for-2020), Cancer (rcdc), Clinical Research (rcdc), Breast Cancer (rcdc), Women's Health (rcdc), 4.2 Evaluation of markers and technologies (hrcs-rac), Cancer (hrcs-hc), Female (mesh), Humans (mesh), Antineoplastic Combined Chemotherapy Protocols (mesh), Biomarkers (mesh), Breast Neoplasms (mesh), Prognosis (mesh), Progression-Free Survival (mesh), Receptor, ErbB-2 (mesh), Thymidine Kinase (mesh), Thymidine kinase, biomarker, disease progression, monitoring treatment, breast cancer, endocrine therapy, Humans (mesh), Breast Neoplasms (mesh), Receptor, erbB-2 (mesh), Thymidine Kinase (mesh), Antineoplastic Combined Chemotherapy Protocols (mesh), Prognosis (mesh), Female (mesh), Biomarkers (mesh), Progression-Free Survival (mesh), Thymidine kinase, biomarker, breast cancer, disease progression, endocrine therapy, monitoring treatment, Female (mesh), Humans (mesh), Antineoplastic Combined Chemotherapy Protocols (mesh), Biomarkers (mesh), Breast Neoplasms (mesh), Prognosis (mesh), Progression-Free Survival (mesh), Receptor, ErbB-2 (mesh), Thymidine Kinase (mesh), 1002 Environmental Biotechnology (for), Toxicology (science-metrix), 3102 Bioinformatics and computational biology (for-2020), 3206 Medical biotechnology (for-2020), 4103 Environmental biotechnology (for-2020)
Dateibeschreibung: application/pdf
-
6
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Leukemia
Schlagwörter: Male, Letter, T-Lymphocytes, Regulatory/immunology, Induction Chemotherapy, CD8-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes/immunology, Prognosis, T-Lymphocytes, Regulatory, Progression-Free Survival, Survival Rate, CD28 Antigens, Antineoplastic Combined Chemotherapy Protocols, Humans, Multiple Myeloma/mortality, 38/32, Multiple Myeloma/pathology [MeSH], 692/308/2779/109/1942, Humans [MeSH], Progression-Free Survival [MeSH], T-Lymphocytes, Regulatory/immunology [MeSH], 101, Antineoplastic Combined Chemotherapy Protocols/therapeutic use [MeSH], Survival Rate [MeSH], Male [MeSH], Multiple Myeloma/immunology [MeSH], Induction Chemotherapy [MeSH], Prognosis [MeSH], letter, 13/31, Multiple Myeloma/mortality [MeSH], CD8-Positive T-Lymphocytes/immunology [MeSH], CD28 Antigens [MeSH], 631/67/1990/804, Multiple Myeloma/drug therapy [MeSH], 45, Antineoplastic Combined Chemotherapy Protocols/therapeutic use, Multiple Myeloma
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38830959
https://repository.publisso.de/resource/frl:6507734
https://biblio.vub.ac.be/vubir/(20e900e9-6f8c-49b9-af53-a622529e4087).html -
7
Autoren: et al.
Quelle: Strahlenther Onkol
Schlagwörter: Male, Aged, 80 and over, Adult, Carcinoma, Hepatocellular, Liver Neoplasms, Radiotherapy Dosage, Carcinoma, Hepatocellular/mortality [MeSH], Liver Neoplasms/surgery [MeSH], Aged, 80 and over [MeSH], Liver Neoplasms/mortality [MeSH], Aged [MeSH], Progression-Free Survival [MeSH], High-dose radiation therapy, Radiosurgery/methods [MeSH], Original Article, Neoplasm Staging [MeSH], Liver Neoplasms/pathology [MeSH], Carcinoma, Hepatocellular/surgery [MeSH], Male [MeSH], Non-invasive oncologic intervention, Carcinoma, Hepatocellular/radiotherapy [MeSH], Female [MeSH], Adult [MeSH], Humans [MeSH], Treatment Outcome [MeSH], Carcinoma, Hepatocellular/pathology [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Primary liver cancer, Precision Oncology, Prognosis [MeSH], Liver Neoplasms/radiotherapy [MeSH], Radiotherapy Dosage [MeSH], Local ablative therapy, Middle Aged, Radiosurgery, Prognosis, Progression-Free Survival, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Humans, Female, Retrospective Studies, Aged, Neoplasm Staging
-
8
Autoren: et al.
Quelle: Br J Cancer
Schlagwörter: Male, Adult, Pulmonary and Respiratory Medicine, 0301 basic medicine, Lung Neoplasms, Pancreatic Cancer Research and Treatment, Advancements in Lung Cancer Research, Diagnosis and Treatment of Lung Cancer, Nursing, FOS: Health sciences, Aged, 80 and over [MeSH], Asian People/genetics [MeSH], Carcinoma, Non-Small-Cell Lung/genetics [MeSH], Aged [MeSH], Lung Neoplasms/genetics [MeSH], Progression-Free Survival [MeSH], Proto-Oncogene Proteins c-met/genetics [MeSH], Piperidines [MeSH], Pyridazines [MeSH], 692/4028/67/1612/1350, Male [MeSH], Quality of Life [MeSH], 692/699/67/1612/1350, Exons [MeSH], Carcinoma, Non-Small-Cell Lung/pathology [MeSH], Female [MeSH], Adult [MeSH], Humans [MeSH], Middle Aged [MeSH], Article, Pyrimidines/therapeutic use [MeSH], Pyrimidines/adverse effects [MeSH], Lung Neoplasms/pathology [MeSH], Carcinoma, Non-Small-Cell Lung/drug therapy [MeSH], Lung Neoplasms/drug therapy [MeSH], article, Adverse effect, 03 medical and health sciences, 0302 clinical medicine, Asian People, Piperidines, Carcinoma, Non-Small-Cell Lung, Health Sciences, 80 and over, Medical Specialties, Medicine and Health Sciences, Humans, Clinical endpoint, Non-Small-Cell Lung, Internal medicine, Aged, Aged, 80 and over, Treatment Guidelines, Quality of life (healthcare), Carcinoma, Cohort, Exons, Middle Aged, Proto-Oncogene Proteins c-met, Progression-Free Survival, 3. Good health, Pyridazines, Clinical trial, Pyrimidines, Oncology, Quality of Life, Medicine, Female, Surgery, Public Health
Dateibeschreibung: application/pdf
-
9
Autoren: et al.
Quelle: New England Journal of Medicine. 388(10)
Schlagwörter: 32 Biomedical and Clinical Sciences (for-2020), 3202 Clinical Sciences (for-2020), 3211 Oncology and Carcinogenesis (for-2020), Cancer (rcdc), Clinical Trials and Supportive Activities (rcdc), Patient Safety (rcdc), Women's Health (rcdc), Pain Research (rcdc), Aging (rcdc), Clinical Research (rcdc), 6.1 Pharmaceuticals (hrcs-rac), Adult (mesh), Female (mesh), Humans (mesh), Amyloid Precursor Protein Secretases (mesh), Antineoplastic Agents (mesh), Double-Blind Method (mesh), Desmoid Tumors (mesh), Gamma Secretase Inhibitors and Modulators (mesh), Progression-Free Survival (mesh), Quality of Life (mesh), Tetrahydronaphthalenes (mesh), Valine (mesh), Humans (mesh), Tetrahydronaphthalenes (mesh), Valine (mesh), Antineoplastic Agents (mesh), Double-Blind Method (mesh), Quality of Life (mesh), Adult (mesh), Female (mesh), Amyloid Precursor Protein Secretases (mesh), Progression-Free Survival (mesh), Gamma Secretase Inhibitors and Modulators (mesh), Desmoid Tumors (mesh), Adult (mesh), Female (mesh), Humans (mesh), Amyloid Precursor Protein Secretases (mesh), Antineoplastic Agents (mesh), Double-Blind Method (mesh), Desmoid Tumors (mesh), Gamma Secretase Inhibitors and Modulators (mesh), Progression-Free Survival (mesh), Quality of Life (mesh), Tetrahydronaphthalenes (mesh), Valine (mesh), 11 Medical and Health Sciences (for), General & Internal Medicine (science-metrix), 32 Biomedical and clinical sciences (for-2020), 42 Health sciences (for-2020)
Dateibeschreibung: application/pdf
-
10
Autoren: et al.
Quelle: Strahlenther Onkol
Schlagwörter: Male, Sarcopenia, Brain Neoplasms, Radiotherapy Planning, Computer-Assisted, Chemoradiotherapy, Middle Aged, Progression-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Sarcopenia/etiology [MeSH], Disease Progression [MeSH], Aged [MeSH], Progression-Free Survival [MeSH], Radiation therapy, Palliative care, Original Article, Tomography, X-Ray Computed [MeSH], Glioblastoma/radiotherapy [MeSH], Male [MeSH], Radiation Dose Hypofractionation [MeSH], Frailty, Brain Neoplasms/mortality [MeSH], Withholding Treatment [MeSH], Female [MeSH], Brain Neoplasms/radiotherapy [MeSH], Computed tomography, Radiotherapy Planning, Computer-Assisted [MeSH], Humans [MeSH], Prognostic biomarker, Retrospective Studies [MeSH], Middle Aged [MeSH], Glioblastoma/therapy [MeSH], Glioblastoma/mortality [MeSH], Body composition, Chemoradiotherapy [MeSH], Brain Neoplasms/therapy [MeSH], Withholding Treatment, Disease Progression, Humans, Female, Radiation Dose Hypofractionation, Glioblastoma, Tomography, X-Ray Computed, Aged, Retrospective Studies
-
11
Autoren: et al.
Weitere Verfasser: et al.
Quelle: Strahlenther Onkol
Schlagwörter: Male, Aged, 80 and over, Adult, Spinal Neoplasms, 610 Medizin, Female [MeSH], Skeletal related events, Spinal Neoplasms/mortality [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Epidural spine compression score, Spinal Neoplasms/surgery [MeSH], Adult [MeSH], Humans [MeSH], Progression-Free Survival [MeSH], Treatment Outcome [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Cancer Pain/etiology [MeSH], Original Article, Spinal Neoplasms/radiotherapy [MeSH], Male [MeSH], Multiple Myeloma/radiotherapy [MeSH], Osteolytic lesions, Spinal surgery, Multiple Myeloma/mortality [MeSH], Spinal bone lesions, Radiotherapy, Adjuvant [MeSH], Cancer Pain/radiotherapy [MeSH], Cancer Pain, Middle Aged, Progression-Free Survival, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, 610 Medical sciences, Humans, Female, Radiotherapy, Adjuvant, Multiple Myeloma, Aged, Retrospective Studies
-
12
Autoren: et al.
Quelle: Virchows Arch
Schlagwörter: Male, Adult, Aged, 80 and over, Squamous Cell Carcinoma of Head and Neck, Middle Aged, Progression-Free Survival, 03 medical and health sciences, 0302 clinical medicine, Carcinoma, Squamous Cell, Humans, Original Article, Mouth Neoplasms, Female, Carcinoma, Squamous Cell/mortality [MeSH], Mouth Neoplasms/classification [MeSH], Female [MeSH], Mouth Neoplasms/pathology [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Squamous Cell Carcinoma of Head and Neck/pathology [MeSH], Adult [MeSH], Humans [MeSH], Progression-Free Survival [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Oral squamous cell carcinoma, Male [MeSH], Squamous Cell Carcinoma of Head and Neck/mortality [MeSH], Staging, Neoplasm Staging/methods [MeSH], Carcinoma, Squamous Cell/pathology [MeSH], Squamous Cell Carcinoma of Head and Neck/classification [MeSH], TNM classification, Carcinoma, Squamous Cell/classification [MeSH], Mouth Neoplasms/mortality [MeSH], UICC, Neoplasm Staging, Aged, Retrospective Studies
-
13
Autoren: et al.
Quelle: Strahlenther Onkol
Strahlentherapie und Onkologie 200(5), 400-408 (2023). doi:10.1007/s00066-023-02180-9Schlagwörter: Male, Adult, Aged, 80 and over, Middle Aged, Radiosurgery, Prognosis, Progression-Free Survival, 3. Good health, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Humans, Original Article, Female, Neoplasm Recurrence, Local, Neoplasm Metastasis, 10. No inequality, Carcinoma, Squamous Cell/mortality [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Progression-Free Survival [MeSH], SABR, Male [MeSH], Carcinoma, Squamous Cell/surgery [MeSH], Carcinoma, Squamous Cell/secondary [MeSH], Carcinoma, Squamous Cell/pathology [MeSH], Carcinoma, Squamous Cell/radiotherapy [MeSH], Neoplasm Metastasis/radiotherapy [MeSH], Female [MeSH], Adult [MeSH], Humans [MeSH], Middle Aged [MeSH], Head and Neck Neoplasms/mortality [MeSH], Radiosurgery [MeSH], Head and Neck Neoplasms/radiotherapy [MeSH], Neoplasm Recurrence, Local/radiotherapy [MeSH], Prognosis [MeSH], Neoplasm metastasis, Metastasis directed therapy, Oligometastasis, Head and Neck Neoplasms/pathology [MeSH], Aged
-
14
Autoren: et al.
Quelle: Strahlenther Onkol
Schlagwörter: Male, Mesothelioma, Aged, 80 and over, Adult, Mesothelioma/mortality [MeSH], Aged, 80 and over [MeSH], Aged [MeSH], Progression-Free Survival [MeSH], Mesothelioma/radiotherapy [MeSH], Trimodal therapy, Organ Sparing Treatments/methods [MeSH], Mesothelioma, Malignant/radiotherapy [MeSH], Original Article, Neoplasm Staging [MeSH], Survival, Male [MeSH], Pleural Neoplasms/mortality [MeSH], Adjuvant radiotherapy, Combined Modality Therapy [MeSH], Radiotherapy, Intensity-Modulated/methods [MeSH], Female [MeSH], Lung Neoplasms/mortality [MeSH], Intensity-modulated radiotherapy, Adult [MeSH], Lung Neoplasms/radiotherapy [MeSH], Humans [MeSH], Treatment Outcome [MeSH], Pleural Neoplasms/radiotherapy [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Lung Neoplasms/surgery [MeSH], Mesothelioma, Malignant/surgery [MeSH], Chemotherapy, Adjuvant [MeSH], Pleural Neoplasms/surgery [MeSH], Pneumonectomy [MeSH], Lung Neoplasms/pathology [MeSH], Mesothelioma/surgery [MeSH], Local tumor control, Lung Neoplasms, Pleural Neoplasms, Mesothelioma, Malignant, Middle Aged, Combined Modality Therapy, Progression-Free Survival, 3. Good health, Treatment Outcome, Chemotherapy, Adjuvant, Humans, Female, Radiotherapy, Intensity-Modulated, Pneumonectomy, Organ Sparing Treatments, Aged, Retrospective Studies, Neoplasm Staging
-
15
Autoren: et al.
Quelle: Eur J Nucl Med Mol Imaging
Schlagwörter: theranostics, Medizin, NETs, Prognosis, Octreotide, Progression-Free Survival, 3. Good health, therapy monitoring, Neuroendocrine Tumors, Treatment Outcome, Neuroendocrine Tumors/diagnostic imaging [MeSH], DOTATOC PET, Organometallic Compounds [MeSH], Humans [MeSH], Progression-Free Survival [MeSH], Theranostics, Treatment Outcome [MeSH], Octreotide [MeSH], Original Article, PRRT, Prognosis [MeSH], Positron Emission Tomography Computed Tomography/methods [MeSH], Therapy monitoring, Neuroendocrine Tumors/metabolism [MeSH], Receptors, Somatostatin/metabolism [MeSH], Positron Emission Tomography Computed Tomography, Organometallic Compounds, Humans, Radiologi och bildbehandling, Receptors, Somatostatin, Radiology, Nuclear Medicine and Medical Imaging
Dateibeschreibung: application/pdf
Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/37947848
https://repository.publisso.de/resource/frl:6522999
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-494338
https://www.ncbi.nlm.nih.gov/pubmed/37947848
https://doi.org/10.1007/s00259-023-06502-y
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85176616389 -
16
Autoren:
Quelle: Pharmacoeconomics
Schlagwörter: Drug Costs [MeSH], Medicare [MeSH], Aged [MeSH], United States [MeSH], Neoplasms/drug therapy [MeSH], Humans [MeSH], Antineoplastic Agents/therapeutic use [MeSH], Progression-Free Survival [MeSH], Original Research Article, Neoplasms, Humans, Antineoplastic Agents, Medicare, United States, Drug Costs, Progression-Free Survival, 3. Good health, Aged
-
17
Autoren: et al.
Quelle: The Lancet. 399(10324)
Schlagwörter: 32 Biomedical and Clinical Sciences (for-2020), 3202 Clinical Sciences (for-2020), 3211 Oncology and Carcinogenesis (for-2020), Clinical Research (rcdc), Women's Health (rcdc), Ovarian Cancer (rcdc), Rare Diseases (rcdc), Clinical Trials and Supportive Activities (rcdc), Cancer (rcdc), 6.1 Pharmaceuticals (hrcs-rac), Cancer (hrcs-hc), Administration, Oral (mesh), Adult (mesh), Aged (mesh), Antineoplastic Combined Chemotherapy Protocols (mesh), Carcinoma, Ovarian Epithelial (mesh), Female (mesh), Humans (mesh), MAP Kinase Kinase 1 (mesh), Middle Aged (mesh), Neoplasm Grading (mesh), Neoplasm Recurrence, Local (mesh), Ovarian Neoplasms (mesh), Paclitaxel (mesh), Progression-Free Survival (mesh), Pyridones (mesh), Pyrimidinones (mesh), Standard of Care (mesh), Treatment Outcome (mesh), United Kingdom (mesh), United States (mesh), Humans (mesh), Ovarian Neoplasms (mesh), Neoplasm Recurrence, Local (mesh), Paclitaxel (mesh), Pyridones (mesh), Pyrimidinones (mesh), MAP Kinase Kinase 1 (mesh), Antineoplastic Combined Chemotherapy Protocols (mesh), Treatment Outcome (mesh), Administration, Oral (mesh), Adult (mesh), Aged (mesh), Middle Aged (mesh), United States (mesh), Female (mesh), Standard of Care (mesh), Neoplasm Grading (mesh), United Kingdom (mesh), Carcinoma, Ovarian Epithelial (mesh), Progression-Free Survival (mesh), Administration, Oral (mesh), Adult (mesh), Aged (mesh), Antineoplastic Combined Chemotherapy Protocols (mesh), Carcinoma, Ovarian Epithelial (mesh), Female (mesh), Humans (mesh), MAP Kinase Kinase 1 (mesh), Middle Aged (mesh), Neoplasm Grading (mesh), Neoplasm Recurrence, Local (mesh), Ovarian Neoplasms (mesh), Paclitaxel (mesh), Progression-Free Survival (mesh), Pyridones (mesh), Pyrimidinones (mesh), Standard of Care (mesh), Treatment Outcome (mesh), United Kingdom (mesh), United States (mesh), 11 Medical and Health Sciences (for), General & Internal Medicine (science-metrix), 32 Biomedical and clinical sciences (for-2020), 42 Health sciences (for-2020)
Dateibeschreibung: application/pdf
-
18
Autoren: et al.
Quelle: Cancer Epidemiology Biomarkers & Prevention. 30(9)
Schlagwörter: 32 Biomedical and Clinical Sciences (for-2020), 3211 Oncology and Carcinogenesis (for-2020), Cancer (rcdc), Rare Diseases (rcdc), Ovarian Cancer (rcdc), Human Genome (rcdc), Women's Health (rcdc), Genetics (rcdc), 2.1 Biological and endogenous factors (hrcs-rac), Cancer (hrcs-hc), Autophagy-Related Protein-1 Homolog (mesh), Biomarkers, Tumor (mesh), Carcinoma, Ovarian Epithelial (mesh), Female (mesh), Gene Knockout Techniques (mesh), Genome-Wide Association Study (mesh), Humans (mesh), Intracellular Signaling Peptides and Proteins (mesh), Ovarian Neoplasms (mesh), Polymorphism, Single Nucleotide (mesh), Progression-Free Survival (mesh), AGO Study Group, OPAL Study Group, for Australian Ovarian Cancer Study Group, Humans (mesh), Ovarian Neoplasms (mesh), Intracellular Signaling Peptides and Proteins (mesh), Polymorphism, Single Nucleotide (mesh), Female (mesh), Genome-Wide Association Study (mesh), Gene Knockout Techniques (mesh), Biomarkers, Tumor (mesh), Autophagy-Related Protein-1 Homolog (mesh), Carcinoma, Ovarian Epithelial (mesh), Progression-Free Survival (mesh), Autophagy-Related Protein-1 Homolog (mesh), Biomarkers, Tumor (mesh), Carcinoma, Ovarian Epithelial (mesh), Female (mesh), Gene Knockout Techniques (mesh), Genome-Wide Association Study (mesh), Humans (mesh), Intracellular Signaling Peptides and Proteins (mesh), Ovarian Neoplasms (mesh), Polymorphism, Single Nucleotide (mesh), Progression-Free Survival (mesh), 11 Medical and Health Sciences (for), Epidemiology (science-metrix), 32 Biomedical and clinical sciences (for-2020), 42 Health sciences (for-2020)
Dateibeschreibung: application/pdf
-
19
Autoren: et al.
Quelle: Clinical Lung Cancer. 22(4)
Schlagwörter: 32 Biomedical and Clinical Sciences (for-2020), 3202 Clinical Sciences (for-2020), 3211 Oncology and Carcinogenesis (for-2020), Clinical Trials and Supportive Activities (rcdc), Cancer (rcdc), Lung (rcdc), Lung Cancer (rcdc), Clinical Research (rcdc), Women's Health (rcdc), 6.1 Pharmaceuticals (hrcs-rac), 6.5 Radiotherapy and other non-invasive therapies (hrcs-rac), Cancer (hrcs-hc), Aged (mesh), Aged, 80 and over (mesh), Antineoplastic Combined Chemotherapy Protocols (mesh), Benzimidazoles (mesh), Carboplatin (mesh), Carcinoma, Non-Small-Cell Lung (mesh), Chemoradiotherapy (mesh), Dose-Response Relationship, Drug (mesh), Female (mesh), Humans (mesh), Lung Neoplasms (mesh), Male (mesh), Middle Aged (mesh), Neoplasm Staging (mesh), Paclitaxel (mesh), Progression-Free Survival (mesh), Survival Rate (mesh), NSCLC, Thoracic radiotherapy, PARP inhibitors, carboplatin, paclitaxel, Humans (mesh), Carcinoma, Non-Small-Cell Lung (mesh), Lung Neoplasms (mesh), Paclitaxel (mesh), Carboplatin (mesh), Benzimidazoles (mesh), Antineoplastic Combined Chemotherapy Protocols (mesh), Neoplasm Staging (mesh), Survival Rate (mesh), Dose-Response Relationship, Drug (mesh), Aged (mesh), Aged, 80 and over (mesh), Middle Aged (mesh), Female (mesh), Male (mesh), Chemoradiotherapy (mesh), Progression-Free Survival (mesh), NSCLC, PARP inhibitors, Thoracic radiotherapy, carboplatin, paclitaxel, Aged (mesh), Aged, 80 and over (mesh), Antineoplastic Combined Chemotherapy Protocols (mesh), Benzimidazoles (mesh), Carboplatin (mesh), Carcinoma, Non-Small-Cell Lung (mesh), Chemoradiotherapy (mesh), Dose-Response Relationship, Drug (mesh), Female (mesh), Humans (mesh), Lung Neoplasms (mesh), Male (mesh), Middle Aged (mesh), Neoplasm Staging (mesh), Paclitaxel (mesh), Progression-Free Survival (mesh), Survival Rate (mesh), 1103 Clinical Sciences (for), 1112 Oncology and Carcinogenesis (for), Oncology & Carcinogenesis (science-metrix), 3202 Clinical sciences (for-2020), 3211 Oncology and carcinogenesis (for-2020)
Dateibeschreibung: application/pdf
-
20
Autoren: et al.
Quelle: Investigational New Drugs. 39(3)
Schlagwörter: 32 Biomedical and Clinical Sciences (for-2020), 3202 Clinical Sciences (for-2020), 3211 Oncology and Carcinogenesis (for-2020), Digestive Diseases (rcdc), Genetics (rcdc), Cancer (rcdc), Pancreatic Cancer (rcdc), Orphan Drug (rcdc), Clinical Research (rcdc), Clinical Trials and Supportive Activities (rcdc), Rare Diseases (rcdc), Precision Medicine (rcdc), 6.1 Pharmaceuticals (hrcs-rac), Cancer (hrcs-hc), Adenocarcinoma (mesh), Administration, Oral (mesh), Aged (mesh), Antineoplastic Agents (mesh), Benzimidazoles (mesh), Female (mesh), Humans (mesh), Kaplan-Meier Estimate (mesh), MAP Kinase Kinase 1 (mesh), MAP Kinase Kinase 2 (mesh), Male (mesh), Middle Aged (mesh), Pancreatic Neoplasms (mesh), Progression-Free Survival (mesh), Protein Kinase Inhibitors (mesh), Selumetinib, MEK inhibitor, Pancreas cancer, KRAS G12 mutational isoform, Phase II, Humans (mesh), Adenocarcinoma (mesh), Pancreatic Neoplasms (mesh), Benzimidazoles (mesh), MAP Kinase Kinase 1 (mesh), MAP Kinase Kinase 2 (mesh), Antineoplastic Agents (mesh), Protein Kinase Inhibitors (mesh), Administration, Oral (mesh), Aged (mesh), Middle Aged (mesh), Female (mesh), Male (mesh), Kaplan-Meier Estimate (mesh), Progression-Free Survival (mesh), KRAS G12 mutational isoform, MEK inhibitor, Pancreas cancer, Phase II, Selumetinib, Adenocarcinoma (mesh), Administration, Oral (mesh), Aged (mesh), Antineoplastic Agents (mesh), Benzimidazoles (mesh), Female (mesh), Humans (mesh), Kaplan-Meier Estimate (mesh), MAP Kinase Kinase 1 (mesh), MAP Kinase Kinase 2 (mesh), Male (mesh), Middle Aged (mesh), Pancreatic Neoplasms (mesh), Progression-Free Survival (mesh), Protein Kinase Inhibitors (mesh), 1115 Pharmacology and Pharmaceutical Sciences (for), Oncology & Carcinogenesis (science-metrix), 3211 Oncology and carcinogenesis (for-2020), 3214 Pharmacology and pharmaceutical sciences (for-2020)
Dateibeschreibung: application/pdf
Full Text Finder 
Nájsť tento článok vo Web of Science 
Full Text